Leclerc, Jacinthe
Blais, Claudia
Rochette, Louis
Hamel, Denis
Guénette, Line
Poirier, Paul
Article History
First Online: 24 November 2018
Compliance with Ethical Standards
:
: Paul Poirier has received honoraria for continuing medical education/consultants/experts events from Abbott Vascular, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Servier, and Valeant. Jacinthe Leclerc, Claudia Blais, Louis Rochette, Denis Hamel and Line Guénette have no potential conflicts of interest that might be relevant to the contents of this manuscript.
: No external funding was used in the preparation of this manuscript as it was part of the continuous chronic disease surveillance mandate in Québec, Canada. Jacinthe Leclerc was the recipient of two PhD studentships during this project: (1) from the <i>Fondation de l’Institut universitaire de cardiologie et de pneumologie de Québec</i>-<i>Université Laval</i> and (2) from the <i>Société Québécoise d’insuffisance cardiaque, alliance BMS</i>-<i>Pfizer</i>. Line Guénette holds a Junior-1 clinical researcher salary award from the FRQ-S in partnership with the <i>Société québécoise d’hypertension artérielle</i>. Paul Poirier is a senior clinical researcher of the <i>Fonds de recherche du Québec</i>-<i>Santé</i> (FRQ-S).